Psoriasis is a chronic, systemic immune-mediated disease characterized by the rapid hyperproliferation of keratinocytes, resulting in the formation of erythematous, scaly plaques. While traditional therapeutic interventions focus on topical corticosteroids, vitamin D analogs, and systemic biologics, the medical community frequently explores off-label applications of existing pharmaceuticals to manage recalcitrant cases. One such substance that has entered the periphery of dermatological discourse is ivermectin. Primarily recognized as a potent broad-spectrum antiparasitic agent, ivermectin has demonstrated secondary immunomodulatory properties that prompt a critical question for patients and clinicians alike: can ivermectin be used for psoriasis effectively?

The rationale behind investigating ivermectin for psoriasis stems from its success in treating inflammatory skin conditions like rosacea, where it targets both Demodex mites and inflammatory pathways. However, psoriasis possesses a distinct pathophysiology driven by the IL-23/IL-17 cytokine axis. To determine if ivermectin has a role in this complex inflammatory landscape, one must analyze its biochemical mechanism, existing clinical literature, and how it compares to established standards of care. This article examines the current scientific consensus and the potential risks associated with using this anthelmintic for autoimmune skin disorders.

Exploring Clinical Evidence: Can Ivermectin Be Used for Psoriasis?

Mechanism of Action: Can Ivermectin Be Used for Psoriasis Pathways?

Ivermectin operates primarily by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells, leading to paralysis and death of the parasite. In human dermatology, however, its utility is attributed to its ability to inhibit the production of pro-inflammatory cytokines. Specifically, studies have shown that ivermectin can reduce the expression of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), both of which play roles in the inflammatory cascade of psoriasis.

Anti-inflammatory Properties vs. Antiparasitic Effects

In conditions like papulopustular rosacea, ivermectin’s efficacy is dual-fold: it eliminates microscopic mites and dampens the innate immune response. For psoriasis, the antiparasitic effect is largely irrelevant unless a patient suffers from a concurrent infestation that exacerbates skin barrier dysfunction. The potential benefit in psoriasis would rely almost exclusively on its capacity to modulate the Th17 immune response, which is the primary driver of plaque formation.

The Role of Cytokines and IL-17

Recent molecular research suggests that ivermectin may interfere with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. Since NF-κB is a critical regulator of the genes involved in the psoriatic inflammatory response, its inhibition could theoretically slow down the recruitment of T-cells to the dermis. While this suggests a theoretical benefit, clinical evidence specifically targeting the IL-17 pathway through ivermectin remains sparse compared to modern monoclonal antibodies.

Comparing Ivermectin to Standard Psoriasis Treatments

To understand where ivermectin might fit in a treatment hierarchy, it is essential to compare its attributes with validated therapies. Most psoriasis patients rely on topical steroids or calcineurin inhibitors for localized plaques. Ivermectin is generally not considered a first-line or even second-line therapy for psoriasis due to its lack of specific FDA approval for this indication.

Ivermectin (Topical)

Treatment Type	Primary Mechanism	Efficacy for Psoriasis	Standard Application
Topical Corticosteroids	Broad immunosuppression	High (Standard)	Twice daily ointment
Vitamin D Analogs	Inhibits keratinocyte growth	High (Standard)	Daily cream
Anti-inflammatory/Antiparasitic	Low/Experimental	Off-label use
Biologics (IL-17 inhibitors)	Targeted cytokine inhibition	Very High	Subcutaneous injection

Clinical Observations and Evidence-Based Perspectives

Currently, there are no large-scale Phase III clinical trials that support the routine use of ivermectin for psoriasis. Most reports available are anecdotal or involve case studies where ivermectin was used to treat comorbid conditions. For instance, in patients suffering from both crusted scabies and psoriasis, ivermectin effectively cleared the infestation, which in turn allowed the psoriatic lesions to respond better to standard topical treatments.

It is important to distinguish between “clearing the skin” and “treating the underlying psoriasis.” If a parasitic infection is causing a Koebner phenomenon—where skin trauma or irritation leads to new psoriatic plaques—ivermectin may indirectly improve the skin’s appearance. However, as a standalone treatment for autoimmune plaque stabilization, the evidence remains insufficient to recommend it over established protocols.

Safety Profiles and Available Formulations

When considering off-label ivermectin, clinicians must choose between oral and topical preparations. Each has a different pharmacokinetic profile and potential for adverse effects. Topical ivermectin (1% cream) is generally well-tolerated with minimal systemic absorption, whereas oral ivermectin requires careful dosing based on body weight and a clear understanding of potential drug-drug interactions.

Formulation	Common Use	Potential Side Effects
Oral Ivermectin	Strongyloidiasis, Scabies	Nausea, dizziness, pruritus
Topical Ivermectin (1%)	Rosacea, Head Lice	Skin burning, irritation, dryness

Key Takeaways for Patients and Providers

• Limited Evidence: There is currently no robust clinical evidence to support ivermectin as a primary treatment for psoriasis.
• Off-Label Risks: Using ivermectin for psoriasis is considered off-label and should only be done under strict medical supervision.
• Inflammatory Overlap: Ivermectin’s anti-inflammatory properties may provide marginal benefits but do not target the specific IL-23/IL-17 axis effectively.
• Prioritize Standard Care: Patients should prioritize FDA-approved treatments such as biologics, phototherapy, and topical steroids which have proven safety and efficacy profiles.

Frequently Asked Questions

Is ivermectin FDA-approved for psoriasis?

No, ivermectin is not FDA-approved for the treatment of psoriasis. It is approved for various parasitic infections and for the inflammatory lesions of rosacea. Any use for psoriasis would be considered off-label and is not supported by current clinical guidelines.

Can topical ivermectin cream help with scalp psoriasis?

There is no evidence to suggest that ivermectin cream is effective for scalp psoriasis. Scalp psoriasis usually requires medicated shampoos, steroid lotions, or systemic treatments that can penetrate the thick plaques characteristic of the condition.

Does ivermectin interact with psoriasis biologics?

While specific interaction studies between ivermectin and psoriasis biologics (like Humira or Stelara) are limited, ivermectin is metabolized by the CYP3A4 enzyme system. Patients on systemic biologics should always consult their dermatologist before introducing any new medication to avoid potential complications or reduced efficacy.

Why do some people claim ivermectin cured their psoriasis?

Claims of “cures” are often anecdotal and may be the result of a misdiagnosis. If a patient actually had a parasitic skin infection that mimicked psoriasis, or if the infection was triggering a psoriasis flare-up, treating the parasites with ivermectin would lead to significant skin improvement.